In conclusion, quercetin at 15μM in vitro and 15 mg/kg BW in vivo, inhibits Akt/mTOR signaling, induces cell cycle arrest, and inhibits BC cell and tumor growth, and appears to be the most active ingredient in the RQC formulation. The gene discussed is AKT1; the disease is breast cancer.